Xilonix™ featured in Antibodies to Watch in 2017
XBiotech’s Phase III study evaluating Xilonix™, the Company’s True Human mAb targeting IL-1 alpha, as a treatment for metastatic colorectal cancer is featured in the annual publication, Antibodies to watch in 2017. As of December 2016, Xilonix™ is one of ten marketing applications for antibody therapeutics that are being evaluated by either FDA or EMA for possible first approvals in the US or EU. XBiotech has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer and is in the process of seeking marketing approval for its lead product candidate with the EMA with a marketing authorization application submission in March 2016. The Company recently submitted responses to Day 180 list of outstanding issues to the EMA and expects an opinion in the second quarter.